ClinicalTrials.gg
CompletedNCT00152958Updated Nov 19, 2013

A Study in Patients Suffering From Idiopathic Restless Legs Syndrome Who Responded to a Preceding, 6-month Treatment With Open-label Pramipexole Including Titration (0.125, 0.25, 0.5, 0.75 mg Orally q.n.)

A Phase 3 interventional study of Pramipexole in Restless Legs Syndrome, sponsored by Boehringer Ingelheim. Completed at 12 sites in Germany. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-11-19.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
224
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing pramipexole in Restless Legs Syndrome — none open to participants now, 1 under way, none of them phase 3. Pramipexole · Restless Legs Syndrome.

Enrollment
8th of 17
224 · median 154
Started
2004
with 2 others
Phase 3
6 of 17
none open now
Registered
3rd of 17
by date
Lead sponsor
12 of 17
Boehringer Ingelheim

Among the 17 studies testing pramipexole in Restless Legs Syndrome, this one is the 8th largest by enrollment, is one of 3 that started in 2004, is one of 6 in phase 3, and was the 3rd registered.

Restless Legs Syndrome

259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.

Browse Restless Legs Syndrome studies →

Open to participants now

None of the 17 studies testing pramipexole in Restless Legs Syndrome is open now. The open studies under Restless Legs Syndrome, anywhere →

About pramipexole

Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing pramipexole in Restless Legs Syndrome as a file.
02

Study summary

The primary objective is to assess sustained efficacy in patients who have responded to a 6 month treatment with open-label pramipexole.

Secondary objectives are the measurement of severity of the RLS, assessment of early withdrawal phenomena after termination of trial medication, augmentation under treatment, sleepiness, quality of life and subjective wellbeing, the physician's clinical assessment of symptom severity and improvement. Another secondary objective is safety and tolerability of treatment.

03

Conditions studied

  • Restless Legs Syndrome
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female out-patients aged 18-80
  • Diagnosis of idiopathic RLS according to the Clinical RLS criteria of the International RLS Study Group
  • RLSRS score > 15
  • RLS symptoms present at least 2 to 3 days per week within the last 3 months
  • Written

Exclusion criteria

Exclusion Criteria:

  • Women of without adequate , or breastfeeding
  • Concomitant or previous pharmacologically therapy of RLS
  • renal disease, and/or hepatic disease
  • Any of the following lab results at screening: , TSH, T3 or T4, clinically significantly out of normal range, positive urine drug screen
  • Other clinically significant metabolic-endocrine (including diabetes mellitus requiring insulin therapy), haematological, gastro-intestinal disease or pulmonary disease . Poorly controlled cardiovascular disease
  • History or clinical signs of peripheral neuropathy (PNP), myelopathy or multiple sclerosis or any other neurological disease, with potential to secondarily cause RLS symptoms, history of or clinical signs for any form of epilepsy or seizures
  • Presence of any sleep disorder
  • History of schizophrenia or any psychotic disorder, history of mental disorders, alcohol abuse or drug addiction
  • History of or clinical signs of malign neoplasm
  • Patients on a shift-work-schedule, or who are otherwise unable to follow a regular sleep-wake cycle enabling use of study medication at times indicated
  • Allergic to pramipexole or its
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
224 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Time to target event (CGI-I rating in association with RLSRS score above 15, period 2) for full analysis set

    Time frame: from randomization up to 3 months

Secondary outcomes

  1. Time to target event for per protocol set (period 2)

    Time frame: from randomization up to 3 months

  2. Number of target events (period 2)

    Time frame: from randomization up to 3 months

  3. Change from baseline (visit 10) in the total score of Restless Legs Syndrome Rating Scale for Severity (RLSRS) (period 2)

    Time frame: from randomization up to 3 months

  4. Clinical Global Impressions - Global Improvement (period 2)

    Time frame: from randomization up to 3 months

  5. Change from baseline (visit 10) in Clinical Global Impressions - Severity of illness score (CGI-S) by 2 or more categories (period 2)

    Time frame: from randomization up to 3 months

  6. Clinical Global Impressions - Therapeutic Effect (CGI-TE) (period 2)

    Time frame: from randomization up to 3 months

  7. Clinical Global Impressions - Side Effects (CGI-SE) (period 2)

    Time frame: from randomization up to 3 months

  8. Change in Patient global impression (PGI) (period 2)

    Time frame: from randomization up to 3 months

  9. Change from baseline (visit 10) in Johns Hopkins Quality of Life (RLS-QoL) score (period 2)

    Time frame: from randomization up to 3 months

  10. Change from baseline (visit 10) in Visual analogue scales (RLS-VASs) for assessment of RLS symptoms (period 2)

    Time frame: from randomization up to 3 months

  11. Change from baseline (visit 10) in Epworth sleepiness scale (ESS)

    Time frame: from randomization up to 3 months

  12. Change from baseline (visit 2) in Augmentation severity rating scale of IRLSSG (ASRS) (period 2)

    Time frame: up to 9 months

  13. Change from baseline ASRS (period 1)

    Time frame: up to 6 months

  14. Change from baseline in the total score of RLSRS (period 1)

    Time frame: up to 6 months

  15. RLSRS responder status by visit (non-responder, partial responder, responder) (period 1)

    Time frame: after 6 months

  16. RLSRS responder status for patients who discontinued the study prematurely in period 1 by reason for discontinuation (period 1)

    Time frame: up to 6 months

  17. Clinical Global Impressions - Global Improvement (period 1)

    Time frame: 6 months

  18. Clinical Global Impressions - Severity of illness score (CGI-S) (period 1)

    Time frame: 6 months

  19. Clinical Global Impressions - Therapeutic Effect (CGI-TE) (period 1)

    Time frame: 6 months

  20. Clinical Global Impressions - Side Effects (CGI-TE) (period 1)

    Time frame: 6 months

  21. Change in patient global impression from baseline (period 1)

    Time frame: 6 months

  22. Change from baseline in Johns Hopkins Quality of Life (RLS-QoL) score (period 1)

    Time frame: 6 months

  23. Change from baseline in RLS-VASs (period 1)

    Time frame: 6 months

  24. Change from baseline in ESS

    Time frame: 6 months

07

Study locations

12 sites
  • Clinpharm International GmbH & Co. KG
    Berlin (Hellersdorf), Germany
  • Boehringer Ingelheim Investigational Site
    Berlin, Germany
  • Charité Campus Virchow-Klinikum
    Berlin, Germany
  • emovis GmbH
    Berlin, Germany
  • Boehringer Ingelheim Investigational Site
    Chemnitz, Germany
  • ClinPharm Internat. GmbH & Co. KG
    Görlitz, Germany
  • Paracelsus-Elena-Klinik
    Kassel, Germany
  • ClinPharm International GmbH & Co. KG
    Leipzig, Germany
  • Neurologische Klinik der Otto-von-Guericke-Universität
    Magdeburg, Germany
  • Universitätsklinikum Giessen und Marburg
    Marburg, Germany
  • Boehringer Ingelheim Investigational Site
    München, Germany
  • Boehringer Ingelheim Investigational Site
    Würzburg, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2004 and a primary completion of Feb 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2005
First posted
Sep 12, 2005
Start
Jan 2004
Primary completionActual
Feb 2005
Last update
Nov 19, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00152958
First posted
Sep 12, 2005
Start date
Jan 2004
Primary completion
Feb 2005
Last update
Nov 19, 2013

Study contacts

Boehringer Ingelheim Study Coordinator
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pramipexole

Start the discussion